Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of MT1011 in Healthy Subjects
NCT07024160Phase 1Recruiting
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hemorrhage comparing MT1011 with Placebo (2 arms). Primary endpoint: Incidence and severity of Adverse Events at Day 14. Started Jun 2025; status: recruiting.
02
Drugs
MT1011
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT07024160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024160.